Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients [Phase 2, Phase 3]
A Phase II/III clinical trial evaluating Adebrelimab in combination with SHR-8068 and chemotherapy for advanced or metastatic non-squamous n…
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure [Phase 2]
Phase 2 trial evaluating serplulimab plus bevacizumab and chemotherapy for EGFR-mutant metastatic non-squamous non-small cell lung cancer af…
-
CLINICAL_TRIALS trial_result · 2024-03-28Clinical Trial Update: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) [Phase 2]
Phase 2 CARMEN-LC04 trial evaluating Tusamitamab Ravtansine with Ramucirumab, with or without Pembrolizumab, in pretreated metastatic non-sm…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating TGF-beta inhibition combined with stereotactic ablative radiotherapy for early stage non-small cell lung cancer h…
-
CLINICAL_TRIALS trial_result · 2024-03-27Clinical Trial Update: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis [Phase 2]
Phase 2 trial evaluating trilaciclib with chemotherapy for advanced non-small cell lung cancer with leptomeningeal metastasis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-26Clinical Trial Update: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer [Phase 2]
A Phase 2 single-arm pilot study evaluating first-line carbognilumab in combination with chemotherapy for STK11-mutated advanced or postoper…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II [Phase 1, Phase 2]
Phase I/II trial evaluating sunvozertinib in combination with chemotherapy for EGFR-mutant NSCLC after EGFR-TKI failure.
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy
Post-marketing surveillance study of nintedanib in Indian patients with non-small cell lung cancer after first-line therapy completed; resul…
-
CLINICAL_TRIALS trial_result · 2024-03-25Clinical Trial Update: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC [Phase 2]
Phase 2 clinical trial investigating trilaciclib in combination with chemotherapy for non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) [Phase 3]
Phase 3 LASER301 trial evaluating Lazertinib as first-line treatment for EGFR mutation–positive locally advanced or metastatic non-small cel…
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) [Phase 3]
Phase 3 trial LASER301 evaluated YH25448 (Lazertinib) as first-line therapy for EGFR mutation-positive locally advanced or metastatic non-sm…
-
CLINICAL_TRIALS trial_result · 2024-03-21Clinical Trial Update: Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) [Phase 3]
Phase 3 trial update evaluating adjuvant targeted therapy guided by ctDNA-MRD in EGFR-mutant non-small cell lung cancer after surgery.
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC [Phase 2]
A Phase 2 study evaluating neoadjuvant nivolumab, with or without ipilimumab, in patients with resectable non-small cell lung cancer; result…
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) [Phase 2]
Phase 2 trial of oral cMET inhibitor INC280 in EGFR wild-type advanced non-small cell lung cancer completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: The Dynamic Monitoring of Cerebrospinal Fluid ctDNA [Phase 2]
Phase 2 clinical trial update investigating dynamic monitoring of cerebrospinal fluid ctDNA in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial update for split-course hypofractionated radiotherapy with concurrent chemotherapy in locally advanced non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for a study evaluating safety, efficacy, and pharmacokinetics in participants with advanced solid tumors, including re…
-
FDA approval · 2024-03-14FDA Approved: TABRECTA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Tabrecta (capmatinib) from Novartis Pharmaceuticals Corporation. The action relates to Tabrecta'…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial evaluating sintilimab plus pemigatinib in PD-L1–positive and FGFR-mutated advanced non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI [Phase 2]
Phase 2 clinical trial update evaluating cadonilimab in non-squamous non-small cell lung cancer patients resistant to EGFR-TKI.
-
CLINICAL_TRIALS research · 2024-03-07Clinical Trial Update: A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 3]
A phase III trial evaluating reduced frequency pembrolizumab therapy as first-line treatment for advanced non-small cell lung cancer is curr…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC [Phase 2]
Phase 2 trial evaluating NT-I7 in combination with atezolizumab for untreated PD-L1-expressing locally advanced or metastatic non-small cell…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC [Phase 2]
Phase 2 trial results for combining stereotactic body radiotherapy (SBRT) with targeted therapy in stage IV oncogene-driven non-small cell l…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer [Phase 2]
Phase 2 clinical trial of FR901228 in patients with refractory or progressive small cell lung cancer or non-small cell lung cancer has compl…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for intravenous T3011 as a single agent and in combination therapy in advanced solid tumors including hepatocellular c…